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Abstract
Background: Periodic outbreaks of dengue fever occur in the United States Virgin Islands. In June 2005, an outbreak of
dengue virus (DENV) serotype-2 with cases of dengue hemorrhagic fever (DHF) was detected in St. Croix, US Virgin Islands.
The objective of this report is to describe this outbreak of DENV-2 and the findings of a case-control study examining risk
factors for DHF.
Methodology/Principal Findings: This is the largest dengue outbreak ever recorded in St. Croix, with 331 suspected
dengue cases reported island-wide during 2005 (62.2 cases/10,000 population); 54% were hospitalized, 21% had at least one
hemorrhagic manifestation, 28% had thrombocytopenia, 5% had DHF and 1 patient died. Eighty-nine laboratory-positive
hospitalized patients were identified. Of these, there were 15 (17%) who met the WHO criteria for DHF (cases) and 74 (83%)
who did not (controls). The only variable significantly associated with DHF on bivariate or multivariable analysis was age,
with an adjusted odds ratio (95% confidence interval) of 1.033 (1.003,1.064).
Conclusions/Significance: During this outbreak of DENV-2, a high proportion of cases developed DHF and increasing age
was significantly associated with DHF.
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Introduction
Dengue fever (DF) is an acute infection caused by any of the
four serotypes of dengue virus (DENV-1, -2, -3 and -4). In the
Americas, the virus is transmitted by Aedes aegypti mosquitoes.
Infection confers transient cross-immunity to all serotypes and
lifelong immunity to the infecting serotype. Each of the four
serotypes can cause DF or the potentially fatal clinical syndrome of
dengue hemorrhagic fever (DHF), characterized by acute febrile
illness with thrombocytopenia, hemorrhage, and capillary leakage.
[1] Although the pathogenesis of DHF is not fully understood, the
most important risk factor is a prior dengue infection. [2] Viral
strain and host factors also play a role. [3,4]
St. Croix, a Caribbean island and the largest (land area of
218 km
2) of the four inhabited United States Virgin Islands (USVI
— St. Croix, St. Thomas, St. John, and Water Island), is located
approximately 60 miles east of Puerto Rico and has a population
of 53,234. [5] The racial and ethnic distribution is 73% Afro-
Caribbean and 27% other/mixed races — 21% of the population
self-identifies as Hispanic or Latino. [5] There are periodic
outbreaks of DENV in the USVI, [6] and DENV-1, -2 and -4
have been detected on separate occasions from 1981 to 1996. [7,8]
Prior to 2005, the most recently documented dengue outbreak
occurred in October 2004 in St. Thomas, when over 40 cases were
reported (CDC, unpublished data).
In June 2005, the Virgin Islands Department of Health
(VIDOH) detected an increase in reported DF cases from St.
Croix, and invited the DB to assist with the outbreak investigation.
The objective of this manuscript is to describe this outbreak of
DENV-2 and the findings of a case-control study examining risk
factors for DHF.
Methods
Ethics Statement
When evaluated by the Institutional Review Board of the CDC,
this non-research activity was considered a component of the
public health response to the dengue outbreak in St. Croix and
thus did not require review. Data analysis was performed on an
anonymized dataset.
Surveillance
Routine surveillance in the USVI relies upon healthcare
provider-initiated requests for dengue laboratory testing submitted
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Dengue Case Investigation Form (DCIF). The DCIF is used to
report basic demographic and pertinent clinical information. The
majority of the suspected dengue cases are reported from the
island’s sole tertiary care hospital, the Governor Juan F. Luis
Hospital and Medical Center (JFL). Located in the capital, this
130-bed healthcare facility services the entire island.
Case definitions
A suspected dengue case was defined as a febrile illness clinically
compatible with DF according to the treating physician. World
Health Organization (WHO) criteria [1] were used to classify
clinical cases of DHF as follows: (1) fever, or a recent history of
fever of 2–7 days duration, accompanied by (2) thrombocytopenia
(#100,000 cells/mm
3), (3) hemorrhage, and (4) objective evidence
of plasma leakage (e.g. pleural effusion or ascites, an abnormally
low serum albumin or protein, or hemoconcentration [defined as
hematocrit values $20% above mean values for sex and age [9] or
$20% increase in hematocrit over the stabilized value at
discharge]).
Laboratory testing
All laboratory testing was performed at the DB. For laboratory
diagnosis of dengue infections, a real-time, reverse transcriptase
PCR assay (RT-PCR, TaqMan Applied Biosystems, Foster City,
California, USA ) [10] or viral culture using C6/36 Aedes albopictus
mosquito cells or tissues from intrathoracically-inoculated adult
Toxorhynchites amboinensis mosquitoes [11,12] was used to identify
virus in serum specimens collected #5 days from the onset of fever
(acute-phase serum specimen). To determine the outbreak strain,
RNA was extracted from tissue culture supernatant (Qiagen).
cDNA was generated using Sensiscript RT-PCR (Qiagen) with
random hexamers (Applied Biosciences). Fourteen pooled over-
lapping 2000 nucleotide (nt) amplicons were generated by RT-
PCR at the DB and sequenced at the Broad Institute by
bidirectional Sanger. [13]
An immunoglobulin M (IgM) antibody-capture enzyme-linked
immunosorbent assay (MAC-ELISA) was also used to detect anti-
dengue IgM antibodies in acute and convalescent-phase (collected
.5 days after the onset of fever) serum specimens. [14] If sufficient
anti-dengue IgM antibodies were detected such that the optical
density was $0.20, [14] this was considered evidence of a recent
dengue infection. Serum specimens were also tested for the
presence of anti-dengue immunoglobulin G (IgG) antibodies using
an IgG ELISA. [15] The presence of anti-dengue IgG antibodies
in acute serum specimens was used to distinguish primary (first)
from secondary (sequential) dengue infections. An IgG titer
$163,840 in a single serum specimen was also considered
laboratory-positive for recent, secondary dengue infections even
without positive virus identification results. [15] There was a
limited supply of dengue antigen in 2005, thus a randomly selected
subset of specimens were tested by IgG ELISA. All suspected
dengue cases with laboratory evidence of an acute or recent
infection were considered laboratory-positive. All suspected
dengue cases with negative acute-phase results and no convales-
cent specimen were classified as indeterminate. All convalescent
specimens that lacked an IgM response were laboratory-negative.
Case-control study
To investigate risk factors for progression to DHF, we
conducted a case-control study among laboratory-positive patients
presenting to the Emergency Department (ED) or admitted to JFL
Hospital during 2005. A case was defined as a laboratory-positive
patient meeting all four WHO criteria for DHF. A control was
defined as a laboratory-positive patient who did not meet criteria
for DHF but was evaluated for thrombocytopenia, plasma leakage
and hemorrhage. Hospitalized patients with negative or indeter-
minate dengue laboratory results were excluded from this analysis.
The medical records of all cases and controls were reviewed. Data
abstracted from the medical records included demographic
information (date of birth, self-reported race on medical records,
etc.) and information on clinical course and outcome. The range of
normal values set by the hospital’s clinical laboratory was used to
define the threshold values for low serum albumin and protein
levels.
Statistical analysis
Data from the case-control study were entered directly into an
electronic form designed using Questionnaire Development
System v2.3 (Nova Research, Bethesda, MD, USA). All data
analysis was then performed using SPSS version 12.0 (SPSS Inc,
Chicago IL, USA) and SAS version 9.1 (SAS Institute, Cary NC,
USA). The Student’s t, Pearson’s chi-squared, Fisher’s exact, and
Mann-Whitney U tests were used to assess unadjusted associations
between study factors and DHF. All variables with a p-value less
than 0.15 in bivariate analysis were included in the final model.
Race [16] was added a priori to the final model. Adjusted odds
ratios (ORs) and 95% confidence intervals (CIs) were calculated
using exact multivariable logistic regression. All tests for
significance were performed at an a-level of 0.05.
Results
Description of Outbreak
Between January 1 and December 31, 2005, 331 suspected DF
cases (62.2 cases/10,000 population) were reported from St. Croix,
USVI with a peak in July (Figure 1). Fifty-three percent were male,
and the median age was 19 years (range: 3 months to 94 years).
Cases were reported island-wide, but the most frequently reported
place of residence (13%) was Williams Delight in southwest St.
Croix. The most commonly reported signs and symptoms in
suspected cases were headache (88%), fever (83%), body pain
(83%), joint pain (68%), chills (56%), and retro-orbital pain (54%).
Fifty-four percent of the suspected cases were hospitalized; 94
(28%) had thrombocytopenia, and 77 (21%) had at least one
hemorrhagic manifestation.
Of the 331 suspected dengue cases, 123 (37%) were laboratory-
positive, 32 (10%) were laboratory-negative, and 176 (53%) were
indeterminate. The overall incidence of laboratory-positive cases
was 23.1/10,000 population. Of the 44 laboratory-positive cases
tested by the IgG ELISA, 3 (7%) were primary infections and 41
(93%) were secondary dengue infections. Fifteen (5%) of the
suspected cases were laboratory-positive and met the WHO
criteria for DHF. Of the 278 specimens tested by RT-PCR, 61
were identified as DENV-2. This was the only serotype identified
from specimens collected during this outbreak. One of the DENV-
2 isolates was sequenced and it corresponded to the southeast
Asian lineage descending from the Jamaican 1983 isolate. [13]
One fatality occurred among the 331 suspected cases. The
patient, a 14 year-old Afro-Caribbean female, presented to the
hospital on day 3 post onset of illness with complaints of fever,
generalized body pain and abdominal pain. Upon admission to the
JFL Hospital, her platelet count was 33,000/mm
3, and within the
first 24 hours, she experienced hematuria, pleural effusions, severe
abdominal pain, cold/clammy skin, and altered mental status. She
suffered circulatory failure then expired soon thereafter. This
patient met WHO criteria for DHF and was found to have had an
acute, secondary dengue infection.
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Eighty-nine laboratory-positive patients were identified from the
JFL Hospital including 15 (17%) who met WHO criteria for DHF
(cases) and 74 (83%) who did not (controls). Of these 89 patients,
30% had at least one hemorrhagic manifestation. Of the 15 DHF
cases, a single patient experienced DHF grade III and the
remainder had grade II. [1] There was no significant difference in
the median length of hospital stay between cases and controls (4.5
vs. 4.0 days, p=0.74). Selected clinical characteristics of cases and
controls are compared in Table 1. Cases and controls were similar
with respect to gender, race, and history of hypertension, diabetes,
or asthma. On bivariate analysis, age was the only variable
significantly associated with DHF (p=0.03). Similarly, in the final
multivariable model (Table 2), age was the only variable associated
with DHF (OR [95% CI]: 1.033 [1.003,1.064]). As age was
considered as a continuous variable in the model, its OR is
interpreted as follows: for every additional year of life, there would
be a 3% increase in the odds of acquiring DHF. As demonstrated
in table 3 and figure 2, there was a higher proportion of DHF
cases in those above the age of 40.
Discussion
An outbreak of dengue fever occurred in the Caribbean island
of St. Croix, USVI during June 2005. This is the largest recorded
dengue outbreak to date in St. Croix and a high incidence of
laboratory-positive infections was observed. In comparison to the
recent large island-wide hyperendemic dengue outbreak in Puerto
Rico, [16] the incidence observed in this outbreak was 2.7 times
greater. Additionally, a high proportion of suspected cases (5%)
met WHO criteria for DHF. In comparison, during the 1981
DENV-2 outbreak in Cuba, the proportion of DHF among
reported cases was approximately 3%. [4] More recently, the
proportion of DHF among reported dengue cases during the
hyperendemic outbreaks of 2007 in the Caribbean states of
Martinique, Guadeloupe, and the Dominican Republic similarly
ranged from 2–3%. [17]
In this investigation, the enhancement of dengue surveillance at
the hospital in St. Croix may have accounted for the increased
proportion of DHF. It may also be explained by the high
proportion of secondary infections, [2] as well as by the virulence
of the circulating strain of dengue. [3] During this outbreak, the
circulating dengue genotype was the southeast Asian strain of
Figure 1. Number of suspected, laboratory-positive, and fatal dengue cases.
doi:10.1371/journal.pone.0013729.g001
Table 1. Bivariate associations between selected factors and
DHF.
Case
n=15
Control
n=74 p-value
Age (mean/years) 36 24 0.03
Male (%) 60 50 0.48
Afro-Caribbean (%) 64 72 0.75
History of hypertension (%) 7 8 1.00
History of diabetes (%) 7 5 1.00
History of asthma (%) 0 8 0.58
Experienced severe abdominal pain (%) 13 1 0.08
Experienced an abrupt change in
temperature (%)
0 3 1.00
doi:10.1371/journal.pone.0013729.t001
Table 2. Multivariable associations with DHF.
Adjusted OR (95% CI) p-value
Age/years 1.033 (1.003,1.064) 0.03
Afro-Caribbean 0.668 (0.185,2.406) 0.54
Experienced severe abdominal pain 9.542 (0.505,180.410) 0.13
doi:10.1371/journal.pone.0013729.t002
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associated with more severe illness. [18]
To our knowledge, this is the first report of an investigation of
the risk factors of DHF in the USVI. In this investigation, age was
the only factor associated with DHF. The higher proportion of
DHF cases in those above the age of 40 suggests that more of these
individuals may have preexisting immunity to another dengue
serotype after a past outbreak in St. Croix. An association between
DHF and age has also been demonstrated using data from Brazil
and Thailand. [19,20] Additionally, there was a protective trend
for Afro-Caribbean race in this study, but this was not statistically
significant. Previous studies have noted that, despite hyperendemic
transmission, DHF is not as prevalent in Haiti (where the majority
of the population is of African descent) or in the African continent
when compared to other tropical areas. [21,22] This may be
partially explained by the lack of consistent surveillance or by the
under-diagnosis of DHF in these areas. In the Cuban dengue
epidemics of 1981 and 2001, Afro-Cubans were at a reduced
risk of severe manifestations of dengue when compared to whites.
[23–25] More recently, it was reported that Afro-Colombians, in
comparison with Mestizos, were less likely to be hospitalized, had
higher platelet counts and lower hematocrit levels. [26] African
ancestry has also been reported to be protective for DHF in Brazil.
[27] Other studies have suggested that, in addition to race, there
are other genetic determinants for severe dengue, ranging from
blood group to expression of human leukocyte antigen (HLA) class
I and II molecules on virus-infected cells. [28–31]
It is very difficult to assess race, and there are inconsistencies
between different studies (e.g., researchers in Brazil used genetic
ancestry as a proxy for race/ethnicity [27] while others in
Colombia determined it by observing the hair type, facial features
and skin color of study participants [26]). This study utilized self-
reported race and, though an imperfect measure, this may be the
most appropriate means of assigning it, [32] especially in the
absence of ancestral genetic markers.
The major limitation of this investigation is the small sample
size and consequent lack of power to detect significant associa-
tions. Moreover, 53% of suspected cases lacked a convalescent
serum specimen and thus yielded indeterminate results from
laboratory testing. Thus, in light of the small population size of St.
Croix and the fact that only 37% of suspected cases were
confirmed, any epidemiologic study on laboratory-positive cases
seeking care at the hospital would be limited by a small sample
size. There were inadequate resources to perform IgG testing on
all specimens; thus the primary/secondary infection status of all
cases and controls could not be ascertained, and this could not be
assessed as a risk factor for DHF. However, increasing age may
have acted as a proxy for secondary infection status. Additionally,
a dengue seroprevalence study was not performed in response to
this outbreak and the true incidence rate of dengue infection could
not be calculated.
Severe dengue disease does occur along a spectrum but clinical
data was insufficient for the non-hospitalized cases and inacces-
sible for those who sought care from private physicians during this
outbreak. Thus, comparisons between severe and mild dengue
cases were not possible. Other limitations include the high degree
of under-reporting due to the passive method of dengue
surveillance in the USVI. As all dengue testing is conducted
outside of the territory, this may act as a further disincentive to
report. Being unable to include data on laboratory-positive
outpatients with dengue fever and the limited sample size and
power of the study may have biased the results of this analysis
towards the null. Conversely, the major strength of the case-
control study was that it focused entirely on hospital-based,
laboratory-positive patients which, through chart review, allowed
for appropriate classification of disease severity.
This investigation provided an excellent opportunity to
investigate the epidemiology of a circumscribed dengue outbreak
in a Caribbean island – despite the increasing frequency of
reported outbreaks in the region, there are few published reports
documenting the unique nature of each outbreak. This is the first
Table 3. Frequency of cases and controls by age-group.
Age/years ,1–9 10–19 20–29 30–39 40–49 50–59 $60
D F 6 3 3 1 6 3474
DHF 2 3 2 0 3 2 3
Total 8 36 18 3 7 9 7
doi:10.1371/journal.pone.0013729.t003
Figure 2. Proportion of DF and DHF cases in the case-control study by age-group.
doi:10.1371/journal.pone.0013729.g002
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Caribbean territory. While it has been reported that persons of
African descent are at reduced risk of DHF, clearly, as reported
here, the population is still at risk of severe dengue and potentially
death. HLA and other markers associated with altered risk of DHF
have been identified, but the reason for this reduced risk among
Afro-Caribbean persons remains elusive. The Caribbean is a
dengue-endemic region and investigating outbreaks in its more
populous multi-ethnic countries (such as Trinidad and Tobago,
Cuba, and the Dominican Republic) would provide an excellent
opportunity to conduct further research on the question of a
dengue resistance gene in those of African descent.
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